Structural insights into the potency of SK channel positive modulators

Young-Woo Nam1, Razan Orfali2, Tingting Liu2,3, Kunqian Yu2,3, Meng Cui4, Heike Wulff5 & Miao Zhang1

Small-conductance Ca2+-activated K+ (SK) channels play essential roles in the regulation of cellular excitability and have been implicated in neurological and cardiovascular diseases through both animal model studies and human genetic association studies. Over the past two decades, positive modulators of SK channels such as NS309 and 1-EBIO have been developed. Our previous structural studies have identified the binding pocket of 1-EBIO and NS309 that is located at the interface between the channel and calmodulin. In this study, we took advantage of four compounds with potencies varying over three orders of magnitude, including 1-EBIO, NS309, SKS-11 (6-bromo-5-methyl-1H-indole-2,3-dione-3-oxime) and SKS-14 (7-fluoro-3-(hydroxyimino)indolin-2-one). A combination of x-ray crystallographic, computational and electrophysiological approaches was utilized to investigate the interactions between the positive modulators and their binding pocket. A strong trend exists between the interaction energy of the compounds within their binding site calculated from the crystal structures, and the potency of these compounds in potentiating the SK2 channel current determined by electrophysiological recordings. Our results further reveal that the difference in potency of the positive modulators in potentiating SK2 channel activity may be attributed primarily to specific electrostatic interactions between the modulators and their binding pocket.

Small-conductance Ca2+-activated K+ (SK) channels are encoded by the KCNN mammalian genes, including KCNN1 for SK1 (KCa2.1), KCNN2 for SK2 (KCa2.2), KCNN3 for SK3 (KCa2.3) and KCNN4 for SK4 (IK or KCa3.1) channels4,5. SK channels resemble voltage-gated potassium channels in their overall tetrameric assembly. There are six transmembrane alpha helical domains that are denoted as S1–S6 in each SK channel subunit. The pore-forming P-loop between the transmembrane S5 and S6 domains is responsible for the potassium ion selectivity. Both the amino- and carboxyl- termini of these channel proteins are on the intracellular side of the plasma membrane. In the proximal carboxyl-terminus of the channels, there is a region called calmodulin binding domain (CaMBD). The Ca2+ binding protein calmodulin (CaM) that is constitutively associated at the CaMBD serves as the Ca2+ sensor of SK channels3. In response to physiological signals, elevated intracellular Ca2+ levels enable Ca2+ binding to CaM, inducing conformational changes in the channel carboxyl-terminus and subsequently opening the channel pore4.6. As such SK channels are not voltage-dependent but instead rely solely on the Ca2+/CaM mediated mechanism described above for their gating. SK channels are therefore often located in close proximity to Ca2+-conducting channels or intracellular Ca2+ sources4,6.

SK channels play essential roles in the regulation of membrane excitability by Ca2+ in both the central nervous and cardiovascular systems1,2. In the cardiovascular system, SK channels in the heart have been shown to contribute to the regulation of the cardiac action potential7,8 while SK channels in the endothelium are implicated in the regulation of vascular tone9–11. In the central nervous system, activation of SK channels generates the medium afterhyperpolarization (mAHP) and reduces the firing frequency of action potentials, thus contributing to the regulation of neuronal excitability12,13. In neurons, SK channels are subject to regulation by posttranslational modification; e.g., phosphorylation. Ca2+ sensitivity of SK channels is reduced by phosphorylation of a specific threonine residue (Thr79) in CaM. The phosphorylation status of CaM Thr79, and thus Ca2+ sensitivity of the channels, is regulated by an interplay between casein kinase 2 and protein phosphatase 2A14,15. For example,
neurotransmitters such as acetylcholine and norepinephrine can induce changes in the phosphorylation status of CaM Thr79, and thus regulate the Ca²⁺ sensitivity of SK channels and neuronal excitability.

The pharmacology of the SK channels is relatively well developed. Apamin, previously considered a blocker, actually acts on the SK channel outer pore through an allosteric mechanism. In contrast, TRAM-34 is in contrast to be a potent inner pore blocker of the IK channel while UCL-1684 and its analogs bind to the outer vestibule of the SK channel. Negative modulation of SK1-3 channel subtypes can be achieved by NS85939, a compound that apparently reduces the Ca²⁺ sensitivity of the channel. Interestingly, the negative gating modifier BU-TRMF exhibits selectivity of the SK1 channel27, whereas RA-2 is a negative modifier for SK3 and IK channel subtypes. On the other hand, positive modulators of SK channels such as 1-ethyl-2-benzimidazolone (1-EBIO) and NS309 can potentiate SK channel activity.

Given the essential roles of SK channels in the cardiovascular system and the central nervous system, SK channels have been proposed as drug targets for the treatment of hypertension and movement disorders. Purkinje cells in the cerebellum are the primary locus of pathology in spinocerebellar ataxia. SK channel positive modulators have been demonstrated to normalize firing rates of cerebellar Purkinje cells through SK2 channel activation and to exert beneficial effects in mouse models of ataxia. Accordingly a significant amount of effort has been devoted to developing small molecules that target SK channels. The prototype 1-EBIO was identified almost two decades ago as a positive modulator. 1-EBIO increases the Ca²⁺ sensitivity of SK channels, which enhances the mAHP and effectively modulates neuronal excitability. A Scandinavian biopharmaceutical company (NeuroSearch A/S) has developed additional compounds, including NS309.

Despite all this progress, it remained unknown where on the SK channels these positive modulators bind, until our previous publications. We first discovered the binding site of 1-EBIO at the CaM-channel interface. This was done using a combination of approaches, including x-ray crystallography, computational biology and electrophysiology. In the crystal structure (PDB Code: 4G28), 1-EBIO bound at the interface of CaMBD and the CaM N-lobe, forming close contacts with both CaM and CaMBD. Later we found that the more potent SK channel positive modulator NS309 also binds into the same binding pocket as 1-EBIO (PDB Code: 49Z2).

Here we describe a trend between the interaction energy (Eint) of the compounds within their binding site calculated from the crystal structures, and the potency (EC₅₀) of these compounds in potentiating the SK2 channel current determined by electrophysiological recordings. This was done utilizing four compounds, 1-EBIO, NS309, SKS-11 (6-bromo-5-methyl-1H-indole-2,3-dione-3-oxime) and SKS-14 (7-fluoro-(3-hydroxyimino)indolin-2-one), varying up to 1000-fold in potency. We investigated the activity of the compounds through electrophysiology and the binding modes by determining x-ray crystal structures of the modulators bound within their binding pocket. Further analysis of the crystal structures show that the strength of electrostatic interactions may be the primary reason why some compounds are more potent than others. Our results provide structural insights into how the potency of SK channel modulators can be improved and thus may facilitate the future development of more potent modulators.

**Results and Discussion**

**The potency of SK channel positive modulators.** Previously we discovered a binding pocket in the SK2 channel shared by two positive modulators 1-EBIO and NS309. In this study, we utilized the crystal structure of the NS309 molecule in complex with its SK2 binding pocket (PDB code: 49Z2) for computer based virtual screening. The Glide module in Maestro was used for virtual screening of the Specs library (www.specs.net), which yielded a list of 30 hit compounds. These compounds were purchased and their effects on the SK2 current were tested using inside-out patch-clamp recordings as previous described.

Two compounds (SKS-11 and SKS-14, Fig. 1a) potentiated the SK2 current (Figs 1b and c). These two positive modulators demonstrated similar efficacy compared to 1-EBIO and NS309 in potentiating the SK2 channels (Supplementary Fig. S2). The maximal responses to the modulators were normalized by the SK2 currents induced by the saturating Ca²⁺ concentration of 10 μM. The normalized maximal responses to NS309, SKS-11, SKS-14 and 1-EBIO were 92.03 ± 3.44% (n = 8), 96.17 ± 4.20% (n = 6) of the currents induced by 10 μM Ca²⁺, respectively (Supplementary Fig. S2). There is no significant difference between the normalized maximal responses of these compounds.

On the other hand, these four modulators differed in their potency (EC₅₀ values) from each other (Supplementary Fig. S2). The concentration-response curves of these modulators are shown in Fig. 1d. The EC₅₀ values of NS309, SKS-11, SKS-14 and 1-EBIO for potentiating SK2 current are 0.552 ± 0.083 μM (n = 8), 3.87 ± 0.88 μM (n = 8), 33.2 ± 4.8 μM (n = 8) and 286 ± 31 μM (n = 6) respectively. NS309 is about 500-fold more potent than 1-EBIO. The potency of SKS-11 and SKS-14 falls between 1-EBIO and NS309. To confirm that the currents that we measured indeed came from the SK2 channel, we utilized apamin. Apamin (20 nM) almost completely abolished the current measured in control experiments (Supplementary Fig. S3).

A moiety shared by the four active compounds is a benzene ring fused with a heterocyclic five-member ring containing at least one nitrogen atom (Fig. 1a). The substituents on the benzene ring include electron withdrawing halogen groups (chloro, bromo and fluoro) and an electron donating methyl group. Fluoro substitution at position 7 (SKS-14), bromo substitution at position 6 (SKS-11) or chloro groups at both position 6 and 7 (NS309)
might direct the distribution of electron density from the neighboring heterocyclic ring. It seems that the compounds with halogen groups at the position 6 and 7 are more potent in potentiating the SK2 channel than compounds lacking halogen substituents in these positions (Fig. 1d).

The shared binding pocket of SK channel positive modulators. We performed virtual screening hoping to discover new scaffolds different from NS309 and 1-EBIO. However, we were only able to identify two active compounds, SKS-11 and SKS-14, which both closely resemble 1-EBIO and NS309 in their chemical structure (Fig. 1a). In future studies, the model needs to be parameterized and trained better to allow for the identification of new scaffolds different from NS309 and 1-EBIO. One possible approach is to utilize multiple conformations of the binding pocket generated from Molecular Dynamics simulations for virtual screening to discover new scaffolds.

The identification of SKS-11 and SKS-14 that closely resemble 1-EBIO and NS309 in structure, however, offers us an opportunity to correlate structure and activity at the atomistic level. To address this question, we first sought to determine the crystal structures of SKS-11 and SKS-14 in complex with their binding pocket (PDB codes, 5WBX and 5WC5). Reminiscent of the binding pockets of 1-EBIO and NS30948,49, the binding site for SKS-11 and SKS-14 is also located at the interface of CaMBD and the CaM N-lobe (Fig. 2a and b). At the CaM-channel interface, between M51, M71, K75 of CaM and L480 of CaMBD, there is extra electron density apparently coming from SKS-11 and SKS-14, respectively. Overlaid conformations of compounds obtained from their respective protein complex structure show subtle but clear differences, especially for 1-EBIO (Fig. 2c and d). Nonetheless, these crystal structures demonstrate that NS309, SKS-11, SKS-14 and 1-EBIO all bind to a shared binding pocket at the CaM-channel interface.

The interaction energy of modulators within the binding pocket. After obtaining crystal structures (Fig. 2) of the binding pocket in complex with compounds of different potency (Fig. 1d and Supplementary Fig. S2), we next explored the interactions between the binding pocket and the compounds and correlated them to the compound potency.

NS309, SKS-11, SKS-14 and 1-EBIO all primarily form contacts with L480 of the CaMBD and with M51, M71 and K75 of CaM. Motivated by the different conformations of the compounds in the binding pocket (Fig. 2), we calculated the interaction energy (E_int) between the compounds and the binding pocket from the crystal structures using Discovery Studio 3.5 molecular modeling program (Accelrys Software Inc.). The total E_int is −43.5 kcal/mol for NS309, −38.8 kcal/mol for SKS-14, −32.6 kcal/mol for SKS-11 and −29.5 kcal/mol for 1-EBIO (Fig. 3a). The total E_int, calculated from the structures of the compound-bound complexes correlates extremely well with the potency (EC50) of the compounds (r = 0.99, Fig. 3b).

In the Discovery Studio 3.5 molecular modeling program, which is using the CHARMM force field, the total interaction energy is defined as the sum of the Van der Waals force (VDW, e.g. repulsion or attraction between atoms) and electrostatic interactions (e.g. interactions due to distribution of the electrons including hydrogen bonds) (Fig. 3a). The interface between CaM and its target protein is relatively hydrophobic4,6,52. It is therefore not surprising that the VDW E_int contributes to a big portion of the total E_int between these compounds and their largely hydrophobic binding pocket. The VDW E_int is −31.2 kcal/mol for NS309, −30.9 kcal/mol for SKS-11, −25.1 kcal/mol for SKS-14 and −27.6 kcal/mol for 1-EBIO (Fig. 3a). On the other hand, the electrostatic E_int is −12.3 kcal/mol for NS309, −7.9 kcal/mol for SKS-11, −7.5 kcal/mol for SKS-14 and −1.8 kcal/mol for 1-EBIO.

Figure 1. SK channel positive modulators. (a) The chemical structures of NS309, 1-EBIO, SKS-11 and SKS-14. (b) Raw current traces of dose-dependent channel potentiation by SKS-11 in the presence of 0.1 μM Ca2+. (c) Raw current traces of dose-dependent channel potentiation by SKS-14 in the presence of 0.1 μM Ca2+. (d) Dose-dependent potentiation of the SK2 current by NS309, SKS-11, SKS-14 and 1-EBIO, respectively. All data are presented in mean ± s.e.m.
The potency of the four compounds is much better correlated with the electrostatic $E_{\text{int}}$ ($r = 0.91$, Fig. 3c) than the VDW $E_{\text{int}}$ ($r = 0.74$, Fig. 3d). As such, even though the VDW $E_{\text{int}}$ contributes a bigger portion to the total $E_{\text{int}}$, the electrostatic $E_{\text{int}}$ is actually the primary reason why these compounds exhibit potency differences.

**The electrostatic interactions of modulators within the binding pocket.** Due to the importance of the electrostatic $E_{\text{int}}$ for the potency differences of the four compounds, we examined the amino acid residues within the binding pocket that form electrostatic interactions with the compounds, namely M51 and K75 from CaM together with A477 from the CaMBD. The oxygen and nitrogen atoms in NS309 (Fig. 4a), SKS-11 (Fig. 4b), SKS-14 (Fig. 4c) and 1-EBIO (Fig. 4d) that form electrostatic interactions are connected by dashed lines with these three residues in the crystal structures. Generally, the distance from these residues is shorter for the more potent compounds (NS309 < SKS-11 < SKS-14 < 1-EBIO, Fig. 4e).

For instance, the distance and angles ($\theta$) from the main chain oxygen of M51 to the nitrogen in the five-member heterocyclic ring is 2.8 angstrom ($\theta = 134.7^\circ$) for NS309, 2.9 angstrom ($\theta = 164.2^\circ$) for SKS-11, 3.1 angstrom ($\theta = 129.7^\circ$) for SKS-14 and 4.1 angstrom ($\theta = 120.6^\circ$) for 1-EBIO. The distance from the main chain oxygen of A477 to the nitrogen in the “=N-OH” group is 3.6 angstrom ($\theta = 129.9^\circ$) for NS309, 4.0 angstrom ($\theta = 105.2^\circ$) for SKS-11 and 4.9 angstrom ($\theta = 92.8^\circ$) for SKS-14. There is no the “=N-OH” group in 1-EBIO (Fig. 1a). The main chain oxygen of A477 may interact weakly with the other nitrogen in the five-member ring with a distance of 4.6 angstrom ($\theta = 90.9^\circ$). The distance from the side chain nitrogen (N) of K75 to the oxygen in the “=N-OH” group is 2.7 angstrom ($\theta = 93.3^\circ$) for NS309, 3.0 angstrom ($\theta = 135.8^\circ$) for SKS-11 and 2.7 angstrom ($\theta = 102.7^\circ$) for SKS-14. 1-EBIO that lacks the “=N-OH” group, may undergo a weak interaction with the side chain nitrogen of K75 through its “=O” group with a distance of 5.3 angstrom.

As electrostatic $E_{\text{int}}$ (e.g. hydrogen bond) is closely related to the length and angle of the interaction, we further examined the electrostatic $E_{\text{int}}$ between the compounds and the three residues. Consistent with our findings from the crystal structures (Fig. 4), M51 and K75 of CaM together with A477 of the CaMBD are the residues that form electrostatic interactions stronger than $-1$ kcal/mol with the compounds. The electrostatic $E_{\text{int}}$ with the M51 is
−4.7 kcal/mol for NS309, −2.3 kcal/mol for SKS-11, −1.6 kcal/mol for SKS-14 and −0.5 kcal/mol for 1-EBIO (Fig. 5a). The electrostatic Eint with the K75 is −4.8 kcal/mol for NS309, −4.9 kcal/mol for SKS-11, −5.9 kcal/mol for SKS-14 and −0.9 kcal/mol for 1-EBIO (Fig. 5b). The electrostatic Eint with the A477 is −2.9 kcal/mol for NS309, −0.3 kcal/mol for SKS-11, −0.7 kcal/mol for SKS-14 and −0.01 kcal/mol for 1-EBIO (Fig. 5c). NS309 is the only compound that forms electrostatic interactions with all three residues with electrostatic Eint stronger than −1 kcal/mol (Fig. 5d), which might explain its high potency in potentiating the SK2 channel (Fig. 1d). Compared to the 6-bromo atom of SKS-11 and 7-fluoro atom of SKS-14, the 6,7-chloro atoms on the benzene ring of NS309 might have enabled optimized the electrostatic interactions between NS309 and the residues of M51, K75 and A477.

Electrostatic interactions such as hydrogen bonds are important specific interactions between ligands and the protein structures, which are often used to improve the efficacy of small molecule drugs through structure-aided drug design. Our results here show that the potency of a series of NS309 analogs correlates extremely well with their Eint, suggesting that one strategy to further improve the potency of SK channel modulators could be to further increase the strength of electrostatic interactions when searching for novel compounds through structure-aided drug design.

**Method**

**Virtual Screening.** The crystal structure of the NS309 molecule in complex with its binding pocket in the CaM/CaMBD complex from the SK2-a channel (PDB code: 4J9Z) was prepared with the workflow of Protein Preparation Wizard implemented in Maestro. Hydrogen atoms were added, followed by optimization of hydrogen bonds. Then energy was optimized to refine improper atoms using the OPLS2005 force field. Afterwards, the generation of a receptor grid was performed with Glide in Maestro. The location of NS309 was used as ligand-binding site. A box with a length of 12 angstroms, which surrounded the ligand-binding site, was set for grid generating.

The Specs library that contains approximately 200,000 compounds was used as the ligand database (www.specs.net). These ligands were filtered with Pipeline Pilot (version 7.5) in the following successive steps. The organic filter and knowledge-based HTS filter were applied for removing inorganic, undesirable and potentially toxic molecules. Then, the application of the Lipinski’s rule of five removed structures unlikely to have drug-like properties. Subsequently, PAINS (pan-assay interference compounds) were removed. The remaining 179,098 compounds were prepared with LigPrep implemented in Maestro, generating possible protonation states and different stereoisomers using Epik at the target pH of 7.0.
The Glide 50 module in Maestro was used for virtual screening. The prepared ligands were docked into the binding pocket with the Standard Precision (SP) mode. During the docking process, dock flexible parameters were selected. The resulting poses were ranked by their glide docking scores. Meanwhile, the NS309 molecule was extracted from the complex structure, prepared, and was docked into the structure with the same parameters, scoring -7.780 in SP mode. In the virtual screening, a total of 10,242 poses scored less than -7 were obtained, which were subsequently redocked into the structure with Extra Precision (XP) mode. The top-ranked 2000 poses were first filtered by removing duplicate molecules. We then clustered the molecules into clusters using fingerprint similarity evaluation in chemical, followed by visual inspection to check the interaction mode for every pose in the complex system (small molecule docking with protein), selecting the rational poses from different clusters. Finally, 30 compounds were purchased from Specs (www.specs.org) for further testing by electrophysiological recordings. Two of them (SKS-11 and SKS-14) potentiated the SK2 current. The remaining 28 compounds did not change the SK2 current. The control compounds NS309 and 1-EBIO were purchased from Tocris. Apamin was purchased from Alomone Labs.

**Electrophysiology**

The electrophysiological recordings of SK2 current were performed as described in our previous papers. Briefly, SK2-a channels, along with CaM and GFP, at a ratio of 5:2.5:1 (weight), were transfected into TsA201 cells by the calcium–phosphate method. SK2 currents were recorded 1–2 days after transfection, with an Axon200B amplifier (Molecular Devices) at room temperature.
pClamp 10.5 (Molecular Devices) was used for data acquisition and analysis. The resistance of the patch electrodes ranged from 3–5 MΩ. The pipette solution contains (in mM): 140 KCl, 10 Hepes (pH 7.4), 1 MgSO₄. The bath solution containing (in mM): 140 KCl, 10 Hepes (pH 7.2), 1 EGTA, 0.1 Dibromo-BAPTA, and 1 HEDTA was mixed with Ca²⁺ to obtain the desired free Ca²⁺ concentrations, calculated using the software by Chris Patton of Stanford University (http://www.stanford.edu/~cpatton/maxc.html). The Ca²⁺ concentrations were verified using Fluo-4 and standard Ca²⁺ buffers (Thermo Fisher Scientific).

Currents were recorded using an inside-out patch configuration. The intracellular face was initially exposed to a zero-Ca²⁺ bath solution, and subsequently to bath solutions with 0.1 μM Ca²⁺. Currents were recorded by repetitive 1-s-voltage ramps from −100 mV to +100 mV from a holding potential of 0 mV. One minute after switching of bath solutions, ten sweeps with a 1-s interval were recorded at a series of concentrations of the compounds in the presence of 0.1 μM Ca²⁺. The maximal SK2 current in response to 10 μM Ca²⁺ was then recorded before the integrity of the patch was examined by switching the bath solution back to the zero-Ca²⁺ buffer. Data from patches, which did not show significant changes in the seal resistance after solution changes, were used for further analysis. To construct the dose-dependent potentiation of channel activities, the current amplitudes at −90 mV in response to various concentrations of the compound were normalized to that obtained at maximal concentration of that compound. The normalized currents were plotted as a function of the concentrations of each compound. EC₅₀ values and Hill coefficients were determined by fitting the data points to a standard dose–response curve (\(Y = 100/(1 + (X/EC_{50})^Hill)\)). All data are presented in mean ± s.e.m. The Student’s t-test was used for data comparison.

Protein crystallization and structure determination. The protein complex consisting of CaM and the SK2 channel fragment (R395–Q486 from rat SK2-a channel) was purified as described in our previous papers. Briefly, rat CaM was introduced into the pET28b(+) vector (Novagen) and expressed in Rosetta-2 E. Coli. cells (Novagen). The CaM protein was purified using a low substitution phenyl sepharose column (GE Healthcare). The SK2 channel fragment was also introduced into the pET28b(+) vector (Novagen) and the codons have been optimized to improve expression of this His-tagged protein in E. Coli. This His-tagged protein was expressed and purified using a Ni-NTA column. The purified SK2 channel fragment was mixed slowly with the purified CaM in the presence of Ca²⁺ to form a complex, followed by purification with a gel filtration column (GE Healthcare) pre-equilibrated in a solution with 10 mM Tris–HCl, 50 mM NaCl, and 10 mM CaCl₂ (pH 7.5). The purified protein complex was concentrated to about 1 mM and then set up for crystallization. Protein crystals of the protein complex were grown in sitting drops by vapour diffusion at 20°C. The complex (1 mM) was

![Figure 5. Electrostatic E_int between the compounds and amino acid residues in their binding pocket. (a) The electrostatic E_int between the compounds and M51. (b) The electrostatic E_int between the compounds and K75. (c) The electrostatic E_int between the compounds and A477. (d) NS309 forms strong electrostatic interactions with three residues M51, K75 and A477.](image-url)
mixed in a 1:1 ratio with the reservoir solution, which consists of 1.5 M Li$_2$SO$_4$, 0.6 M (NH$_4$)$_2$SO$_4$, 0.1 M sodium citrate, pH 5.8. Monoclinic crystals usually grew within 3 weeks. These preformed protein crystals were then incubated with SK channel modulators at their saturating concentrations for ~1 month (SKS-11) and ~5 months (SKS-14), respectively. The soaked protein crystals were flash-cooled in liquid nitrogen for data collection, after a brief transfer to a suitable cryoprotectant (25% glycerol with the reservoir solution saturated with SKS-11 or SKS-14). X-ray diffraction data were collected from single crystals on the X-ray diffraction system (DE Venture Diffraction System, Bruker AXS Inc.) at our home institute and processed using PROTEUM2 (Bruker AXS Inc.). Initial phases were determined by molecular replacement (MR) using PHASER from the CCP4 suite61. Our previously determined CaM/CaMBD complex structure (4J9Y) was used as a starting model to phase diffraction data. Solvent molecules were removed from the soaked molecule before rigid body refinement. The crystallographic model was further constructed through iterative rounds of manual model-building using Coot62 and crystallographic refinement using REFMAC61 and PHENIX63. SKS-11 and SKS-14 were modeled respectively in a pocket at the CaM-channel interface based on strong electron density in difference Fourier maps and followed by successful refinement of the coordinates. The crystallographic statistics for data collection and model refinement are summarized in Supplementary Table 1. Structure graphics were created using PyMol (Schrödinger, LLC).

**Interaction Energy Calculation.** The Discovery Studio 3.5 molecular modeling program (Accelrys Software Inc.) was used to conduct energy minization and calculate the interaction energy between the compound and the protein complex. All structures were subjected to energy minization using Smart Minimizer algorithm (2000 steps), and Generalized Born (GB) implicit solvent model using the CHARMM force field. Interaction energies between the compound and the protein complex were calculated using a distance dependent dielectric constant ($\varepsilon = 2r$) implicit solvent model. The decomposed interaction energy contribution of residues to the total interaction energy was analyzed to identify the critical interacting amino acid residues in the protein complex.

**Data availability.** The structure coordinates have been deposited in the Protein Data Bank under accession codes SWBX and SWC5.

**References**

1. Stocker, M. Ca$^{2+}$-activated K$^+$ channels: molecular determinants and function of the SK family. Nat Rev Neurosci 5, 758–770 (2004).
2. Adelman, J. P., Maylie, J. & Sah, P. Small-conductance Ca$^{2+}$-activated K$^+$ channels: Form and function. Annu Rev Physiol 74, 245–269 (2012).
3. Kohler, M. et al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science 273, 1709–1714 (1996).
4. Schumacher, M. A., Rivard, A. F., Bachinger, H. P. & Adelman, J. P. Structure of the gating domain of a Ca$^{2+}$-activated K$^+$ channel complexed with Ca$^{2+}$/calmodulin. Nature 410, 1120–4 (2001).
5. Li, W., Halling, D. B., Hall, A. W. & Aldrich, R. W. EF hands at the N-lobe of calmodulin are required for both SK channel gating and stable SK-calmodulin interaction. J Gen Physiol 134, 281–93 (2009).
6. Zhang, M. et al. Structural basis for calmodulin as a dynamic calcium sensor. Structure 20, 911–23 (2012).
7. Zhang, X. D., Lieu, D. K. & Chiamvimonvat, N. Small-conductance Ca$^{2+}$-activated K$^+$ channels and cardiac arrhythmias. Heart Rhythm 12, 1845–51 (2015).
8. Li, N. et al. Ablation of a Ca$^{2+}$-activated K$^+$ channel (SK2 channel) results in action potential prolongation in atrial myocytes and atrial fibrillation. J Physiol 587, 1087–100 (2009).
9. Xu, Y. et al. Molecular Identification and Functional Roles of a Ca$^{2+}$-activated K$^+$ Channel in Human and Mouse Hearts. J Biol Chem 278, 49085–49094 (2003).
10. Chang, P. C. et al. Heterogeneous upregulation of apamin-sensitive potassium currents in failing human ventricles. J Am Heart Assoc 2, e004713 (2013).
11. Chua, S. K. et al. Small-conductance calcium-activated potassium channel and recurrent ventricular fibrillation in failing rabbit ventricles. Circ Res 108, 971–9 (2011).
12. Taylor, M. S. et al. Altered expression of small-conductance Ca$^{2+}$-activated K$^+$ (SK3) channels modulates arterial tone and blood pressure. Circ Res 93, 124–31 (2003).
13. Feng, J. et al. Calcium-activated potassium channels contribute to human coronary microvascular dysfunction after cardioplectic arrest. Circulation 118, S46–51 (2008).
14. Sonkusare, S. K. et al. Elementary Ca$^{2+}$-signaling through endothelial TRPV4 channels regulate vascular function. Science 336, 597–601 (2012).
15. McNeill, A. J. et al. Evidence for involvement of both IKCa and SKCa channels in hyperpolarizing responses of the rat middle cerebral artery. Stroke 37, 1277–82 (2006).
16. Pedarzani, P. et al. Control of Electrical Activity in Central Neurons by Modulating the Gating of Small Conductance Ca$^{2+}$-activated K$^+$ Channels. J Biol Chem 276, 9762–9769 (2001).
17. Bild, W. et al. Protein kinase CK2 Is coassembled with small conductance Ca$^{2+}$-activated K$^+$ channels and regulates channel gating. Neuron 43, 847–858 (2004).
18. Giesel, A. J. & Sabatini, B. L. M1 muscarinic receptors boost synaptic potentials and calcium influx in dendritic spines by inhibiting postsynaptic SK channels. Neuron 68, 936–47 (2010).
19. Maingret, F. et al. Neurotransmitter Modulation of Small-Conductance Ca$^{2+}$-Activated K$^+$ Channels by Regulation of Ca$^{2+}$-activated Gating. Neuron 59, 439–449 (2008).
20. Weatherall, K. L., Seulin, V., Liegeois, J. F. & Marrion, N. V. Crucial role of a shared extracellular loop in apamin sensitivity and maintenance of pore shape of small-conductance calcium-activated potassium (SK) channels. Proc Natl Acad Sci USA 108, 18494–9 (2011).
21. Lamé, C. et al. Allosteric block of KaCa2 channels by apamin. J Biol Chem 285, 27067–77 (2010).
22. Wulff, H., Gutman, G. A., Cahalan, M. D. & Chandy, K. G. Delineation of the C10TRIM43-TRAM-34 Binding Site on the Intermediate Conductance Calcium-activated Potassium Channel, IKCa1. J Biol Chem 276, 32040–32043 (2001).
23. Nguyen, H. M. et al. Structural Insights into the Atomic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore. Mol Pharmacol 91, 392–402 (2017).
24. Fanger, C. M. et al. Calcium-activated Potassium Channels Sustain Calcium Signaling in T Lymphocytes. SELECTIVE BLOCKERS AND MANIPULATED CHANNEL EXPRESSION LEVELS. J Biol Chem 276, 12249–12256 (2001).
25. Stroebek, D. et al. Inhibitory Gating Modulation of Small Conductance Ca$^{2+}$-Activated K$^+$ Channels by the Synthetic Compound (R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) Reduces Afterhyperpolarizing Current in Hippocampal CA1 Neurons. Mol Pharmacol 70, 1771–1782 (2006).
26. Sorensen, U. S. et al. Synthesis and structure–activity relationship studies of 2-((N-substituted)-amino benzimidazoles as potent negative gating modulators of small conductance Ca2+–activated K+ channels. J Med Chem 51, 7625–34 (2008).
27. Hougaard, C. et al. Evidence for a common pharmacological interaction site on KCa2.2 channels providing both selective activation and selective inhibition of the human KCa2.1 subtype. Mol Pharmacol 81, 210–9 (2012).
28. Olivan-Viguera, A. et al. Novel phenolic inhibitors of small/intermediate-conductance Ca2(2+)-activated K+(+) channels, KCa3.1 and KCa3.2. PLoS One 8, e58614 (2013).
29. Devor, D. C., Singh, A. K., Frizell, R. A. & Bridges, R. J. Modulation of Cl– secretion by benzimidazolones. I. Direct activation of a Ca2(2+)-dependent K+ channel. Am J Physiol 271, L775–84 (1996).
30. Ströbäck, D. et al. Activation of human IK and SK Ca2+–activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxide). Biochim Biophys Acta 1665, 1–5 (2004).
31. Damkjaer, M. et al. Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs. Br J Pharmacol 165, 223–34 (2012).
32. Hasenau, A. L. et al. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2+-activated K+ channels. Acta Physiol (Oxf) 203, 117–26 (2011).
33. Kohler, R., Raitha, B. P. & Wulf, H. Vascular KCa channels as therapeutic targets in hypertension and restenosis disease. Expert opinion on therapeutic targets 14, 143–55 (2010).
34. Sankaranarayanan, A. et al. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 75, 281–95 (2009).
35. Wulff, H. & Kohler, R. Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets. J Cardiovasc Pharmacol 61, 102–13 (2013).
36. Luna-Cancalon, K. et al. Alterations in cerebellar physiology are associated with a stiff-legged gait in Atacy(ji-hes) mice. Neurobiol Dis 67, 140–8 (2014).
37. Dimitriadi, M. et al. Conserved genes act as modifiers of invertebrate SMN loss of function defects. PLoS Genet 6, e1001172 (2010).
38. Dimitriadi, M. et al. The neuroprotective drug riluzole acts via small conductance Ca2+–activated K+ channels to ameliorate defects in spinal muscular atrophy models. J Neurosci 33, 6557–62 (2013).
39. Kasamu, A. W. et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem Biol 19, 1340–53 (2012).
40. Walter, T. F., Alvina, K., Womack, M. D., Chevez, C. & Khodakhah, K. Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunctions and ataxia. Nat Neurosci 9, 389–97 (2006).
41. Shakkottai, V. G. et al. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci 31, 13002–14 (2011).
42. Geschwind, D. H., Perlman, S., Figueroa, C. P. & Pulst, S. M. The prevalence and wide clinical spectrum of the spinocerebellar ataxia. J Neurosci 30, 271, 842–50 (1977).
43. Lastres-Becker, I., Rub, U. & Auburger, G. Spinocerebellar ataxia type 2. Adv Exp Med Biol 530, 1–12 (2004).
44. Alvina, K. & Khodakhah, K. KCa channels as therapeutic targets in episodic ataxia type-2. J Neurosci 30, 2719–27 (2010).
45. Pedarzani, P. & Stocker, M. Molecular and cellular basis of small- and intermediate-conductance, calcium-activated potassium channel function in the brain. Cell Mol Life Sci 65, 3196–3217 (2008).
46. Pedarzani, P. et al. Specific enhancement of calcium activity selectively potentiates the afterhyperpolarizing current (IAPH) and modulates the firing properties of hippocampal pyramidal neurons. J Biol Chem 280, 41404–11 (2005).
47. Zhang, M., Pascal, J. M., Schumann, M., Arment, R. S. & Zhang, J. F. Identification of the functional binding pocket for compounds targeting small-conductance Ca(2)(2+)-activated potassium channels. Nat Commun 3, 1021 (2012).
48. Zhang, M., Pascal, J. M. & Zhang, J. F. Unstructured to structured transition of an intrinsically disordered protein peptide in coupling Ca2+–sensing and SK channel activation. Proc Natl Acad Sci USA 110, 4828–33 (2013).
49. Halgren, T. A. et al. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. J Med Chem 57, 8143–53 (2014).
50. Wulff, H. & Kohler, R. Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets. J Cardiovasc Pharmacol 61, 102–13 (2013).
51. Zhang, M., Meng, X. Y., Zhang, J. F., Cui, M. & Logothetis, D. E. Molecular overlap in the regulation of SK channels by small molecules and phosphonoinositides. Sci Adv 1, e1500008 (2015).
52. Schumacher, M. A., Crum, M. & Miller, M. C. Crystal structures of apocammodulin and an apocammodulin/SK potassium channel gating domain complex. Structure 12, 849–860 (2004).
53. Patil, R. et al. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLoS One 5, e12029 (2010).
54. Bissantz, C., Kuhn, B. & Stahl, M. A medicinal chemist’s guide to molecular interactions. J Med Chem 53, 5061–84 (2010).
55. Pilot, P. version 7.5. Accelrys: San Diego, CA (2008).
56. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development. Advanced Drug Delivery Reviews 45, 5–26 (2001).
57. Altmann, H. Supporting PAINS in academic drug discovery. Future Medicinal Chemistry 3, 797–801 (2011).
58. Baell, J. B. & Holloway, G. A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. J Med Chem 53, 2719–2740 (2010).
59. Release, S. I. Maestro, version 10.1. Schrödinger, LLC, New York, NY (2015).
60. Zhang, M. et al. Selective phosphorylation modulates the PI2P2 sensitivity of the CaM-SK channel complex. Nat Chem Biol 10, 753–9 (2014).
61. Collaborative Computational Project, N. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50, 760–3 (1994).
62. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 2126–32 (2004).
63. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213–21 (2010).

Acknowledgements
We thank Drs. K. Parang and S. Rahighi for helpful comments on the manuscript. We are grateful to Sara Ali, Tia Alexander, Kristy Harada, Melody Ra, Sara Siwiecki, Adam Viegas and Benji Whitmore for technical assistance. We thank Drs. M. Benning and I. Maslenikov for help with x-ray crystallography data collection. K.Y. is supported by National Science and Technology Major Projects for “Major New Drugs Innovation and Development” [2017ZX09101005-003-005], National Key R&D Program of China (2016YFB0201700). H.W. is supported by grant R21NS101876 from NIH. M.Z. is supported by a Scientist Development Grant 13SDG1615007 from American Heart Association, a YI-SCA grant from National Ataxia Foundation and an IGNITE grant R21NS101182 from NIH.
Author Contributions
Y.W.N. and M.Z. did experiments of x-ray crystallography and the structure determination. T.L., K.Y., and M.C. performed computational work. R.O. and M.Z. carried out experiments of electrophysiology. Y.W.N., H.W. and M.Z. prepared the manuscript and the figures.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-16607-8.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017